mura in 1

MurA-IN-1 (compound 1a), a PTPRR inhibitor, exhibits IC50 values of 0.09 μM for PTPRR, 0.23 μM for PTP1B, 0.75 μM for PTPN7, and 0.8 μM for PTPN5, respectively, targeting a family of human MAPK-specific protein tyrosine phosphatases[1].

Feglymycin is a 13-amino acid peptide originally isolated from Streptomyces that has antibacterial and antiviral activities. It is active against Gram-positive bacteria (MICs = 32-64 μg/ml) and inhibits HIV viral replication in H9 cells (IC50 = ~5 μM). Feglymycin is also active against clinical isolates of HIV-1 from clades A-D, A/E, and G (EC50s = 0.5-6.7 μM). It interacts with gp120 and inhibits HIV-1 NL4.3 binding to human soluble CD4 (EC50 = 4.4 μM) and to CD4+ SupT1 T cells by 74.5% when used at a concentration of 10.5 μM. Feglymycin inhibits the E. coli peptidoglycan biosynthesis enzymes MurA and MurC (Kis = 3.4 and 0.3 μM, respectively) in a noncompetitive manner.

MurA-IN-2 (compound 37), a potent MurA inhibitor featuring a chloroacetamide fragment with a primary aliphatic amine, exhibits antibacterial activity by inhibiting bacterial cell wall synthesis, with an IC50 of 39 μM [1].

MurA-IN-3, a reversible pyrrolidinedione-based MurA inhibitor, exhibits an IC50 of 4.5 μM against MurA and demonstrates antibacterial activity [1].

MurA-IN-4 exhibits antibacterial properties as a MurA inhibitor, impeding the synthesis of bacterial cell walls [1].